Global Premature Ejaculation Therapeutics Market Report 2024-2029: North America and Europe Dominate the Market in 2023, APAC Emerges as the Fastest-Growing Market
The global premature ejaculation therapeutics market was valued at $2,456.71 million in 2023 and is expected to reach $4,062.34 million by 2029, growing at a CAGR of 8.74%. The market growth is mainly attributed to the rising prevalence of premature ejaculation among men globally.
This report offers market size & forecast data for the global premature ejaculation therapeutics market. The revenue generated from the sale of drugs, including off-label products, is included in the report.
The revenue generated from the devices used to manage premature ejaculation, physicians' fees, and other service-related costs is excluded from the report's scope. This report provides a comprehensive and current market scenario of the global premature ejaculation therapeutics market, including the global premature ejaculation therapeutics market size, anticipated market forecast, relevant market segmentations, and industry trends.
The study considers a detailed scenario of the present global premature ejaculation therapeutics market and its market dynamics for 2024?2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.
KEY HIGHLIGHTS
In 2023, North America and Europe dominated the market with a market share of 43.79% and 25.02%, respectively. APAC is expected to be the fastest-growing market for premature ejaculation (PE) therapeutics in terms of revenue during the forecast period, with a CAGR of 10.56%.
By drug class, the Selective Serotonin Reuptake Inhibitors (SSRIs) segment was valued at $1,064.41 million in 2023 and is expected to reach $1,759.00 million by 2029, growing at a CAGR of 8.73%. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide. SSRIs are considered effective drugs for the treatment of premature ejaculation therapeutics market.
By Route of Administration, the oral therapeutics segment was valued at $1,847.37 million in 2023 and is expected to reach $2,975.67 million by 2029, growing at a CAGR of 8.27%. The increased recommendation of oral therapeutics by healthcare professionals is one of the key factors for the growth of the segment worldwide. Also, the growing pervasiveness of premature ejaculation and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.
By age group, the people aged below 45 years segment was valued at $1,519.11 million in 2023 and is expected to reach $2,536.12 million by 2029, growing at a CAGR of 8.92%. The rise in the prevalence of premature ejaculation in the younger population is the major factor contributing to the market growth during the forecast period.
Plethora Solutions, Pfizer, Eli Lilly and Company, GSK plc, and the Menarini group are some leading players currently dominating the global premature ejaculation therapeutics market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the premature ejaculation therapeutics market and access commercially launched products.
VENDORS LIST
Plethora Solutions
Pfizer
Absorption Pharmaceuticals
Eli Lilly and Company
GSK plc
Bayer AG
MidasCare
Pound International
Momentum Management
Reckitt Benckiser Group
Recordati
Royalty Pharma
Shibari
Johnson & Johnson
The Menarini Group
Futura Medical
Niksan Pharmaceuticals
Amneal Pharmaceuticals
Key Topics Covered:
1: Pe Therapeutics Market Overview
Executive Summary
Key Findings
2: Pe Therapeutics Market
Global: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
3: Pe Therapeutics Market Segmentation Data
Global: Projected Revenue by Drug Class (2023-2029; $Millions)
Ssris
Pde-5 Inhibitors
Anesthetic Agents
Others
Global: Projected Revenue by Route of Administration (2023-2029; $Millions)
Oral Therapeutics
Topical Therapeutics
Global: Projected Revenue by Age Group (2023-2029; $Millions)
Below 45 Years
Above 45 Years
4: Key Regions Overview
North America: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
Projected Revenue of Pe Therapeutics Market in US
Projected Revenue of Pe Therapeutics Market in Canada
Europe: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
Projected Revenue of Pe Therapeutics Market in Germany
Projected Revenue of Pe Therapeutics Market in UK
Projected Revenue of Pe Therapeutics Market in France
Projected Revenue of Pe Therapeutics Market in Italy
Projected Revenue of Pe Therapeutics Market in Spain
APAC: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
Projected Revenue of Pe Therapeutics Market in Japan
Projected Revenue of Pe Therapeutics Market in India
Projected Revenue of Pe Therapeutics Market in China
Latin America: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
Projected Revenue of Pe Therapeutics Market in Brazil
Projected Revenue of Pe Therapeutics Market in Mexico
Projected Revenue of Pe Therapeutics Market in Argentina
Middle East & Africa: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
Projected Revenue of Pe Therapeutics Market in Turkey
Projected Revenue of Pe Therapeutics Market in Saudi Arabia
Projected Revenue of Pe Therapeutics Market in South Africa
5: Pe Therapeutics Market Prospects & Opportunities
Pe Therapeutics Market Opportunities & Trends
Pe Therapeutics Market Drivers
Pe Therapeutics Market Constraints
6: Pe Therapeutics Industry Overview
Pe Therapeutics Market - Competitive Landscape
Pe Therapeutics Market - Key Vendor Profiles
Pe Therapeutics Market - Other Prominent Vendors
Pe Therapeutics Market - Key Strategic Recommendations
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact: Research and Markets Laura Wood, Senior Manager [email protected]
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI...
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...